Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresec…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05677490
Sites in Texas: - Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- Tarrant County Hospital District/JPS Health Network — Fort Worth, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from wh…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06203600
Sites in Texas: - Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
- Ben Taub General Hospital — Houston, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Texas: - Research Site — Dallas, Texas
- Research Site — Sherman, Texas
Phase 2, Phase 3 Recruiting Industry
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to o…
Sponsor: Pfizer
NCT ID: NCT07392892
Sites in Texas: - US Oncology Investigational Products Center (IPC) — Irving, Texas
- US Oncology Investigational Products Center (IPC) — Irving, Texas
Phase 3 Recruiting Industry
This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, a…
Sponsor: AstraZeneca
NCT ID: NCT06764875
Sites in Texas: - Research Site — Dallas, Texas
- Research Site — Webster, Texas
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic gastric, gast…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221149
Sites in Texas: - Texas Oncology - Amarillo Cancer Center — Amarillo, Texas
- Texas Oncology-Austin Central — Austin, Texas
- Texas Oncology — Beaumont, Texas
- Texas Oncology - Northeast Texas — Denison, Texas
- Texas Oncology - DFW — Grapevine, Texas
Phase 3 Recruiting Industry
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2…
Sponsor: RayzeBio, Inc.
NCT ID: NCT05477576
Sites in Texas: - Research Facility — Houston, Texas
Phase 3 Recruiting Industry
This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with HER2-positi…
Sponsor: Shanghai Henlius Biotech
NCT ID: NCT06532006
Sites in Texas: - Texas Oncology - West (SCRI) — Abilene, Texas
- Texas Oncology Central South (SCRI) — Austin, Texas
- Texas Oncology Northeast (SCRI) — Denton, Texas
- The University of Texas MD Anderson cancer Center — Houston, Texas
- Texas Oncology - Gulf Coast (SCRI) — Webster, Texas
Phase 3 Recruiting Industry
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with chemotherapy may be used to treat stomach …
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT06901531
Sites in Texas: - Texas Oncology-Baylor Charles A Sammons Cancer Center — Dallas, Texas
- The Center For Cancer And Blood Disorders (Texas Cancer Care) — Fort Worth, Texas
- Houston Methodist Cancer Center — Houston, Texas
Phase 3 Recruiting Industry
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+),…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06784752
Sites in Texas: - TxO Austin Midtown — Austin, Texas
- Texas Oncology — Dallas, Texas
Phase 3 Recruiting Industry
This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus tr…
Sponsor: Daiichi Sankyo
NCT ID: NCT06731478
Sites in Texas: - UT Southwestern Medical Center — Dallas, Texas
- Texas Oncology, P.A. - Tyler — Tyler, Texas
Phase 2 Recruiting Industry
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're …
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT06157892
Sites in Texas: - Parkland Health and Hospital System — Dallas, Texas
- University of Texas Southwestern Medical Center - Simmons Cancer Center — Dallas, Texas
- University of Texas Southwestern Medical Center-Simmons Cancer Center Pharmacy — Dallas, Texas
- University of Texas Southwestern Medical Center Simmons Cancer Center - Redbird — Dallas, Texas
- University of Texas Southwestern Medical Center Clinical Lab-Zale Lipshy University Hospital — Dallas, Texas
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Texas: - Clinical Trial Network — Houston, Texas
- Oncology and Hematology of South Texas, PA — Laredo, Texas
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Texas: - The Methodist Hospital Research Institute — Houston, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…
Sponsor: Merus B.V.
NCT ID: NCT03526835
Sites in Texas: - Texas Oncology — Dallas, Texas
- Oncology Consultants — Houston, Texas
- Texas Oncology — Tyler, Texas
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Texas: - Mary Crowley Cancer Research — Dallas, Texas
- MD Anderson — Houston, Texas
- NEXT Dallas — Irving, Texas
- NEXT Oncology San Antonio — San Antonio, Texas
- START Texas — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Texas: - The University of Texas, MD Anderson Cancer Center — Houston, Texas
- UT Health Mays Cancer Center — San Antonio, Texas
Phase 2 Recruiting Industry
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Sponsor: AstraZeneca
NCT ID: NCT05489211
Sites in Texas: - Research Site — Houston, Texas
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Texas: - Texas Oncology - West Texas — Amarillo, Texas
- Texas Oncology, P.A. — Dallas, Texas
- Texas Oncology Gulf Coast — Pearland, Texas
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Texas: - Texas Oncology - West Texas — Amarillo, Texas
- Texas Oncology - DFW — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- Texas Oncology - San Antonio — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytological…
Sponsor: BioNTech SE
NCT ID: NCT07070232
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas
- South Texas Accelerated Research Therapeutics (START), LLC — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific KRAS mutation. This is an open-label study which means that participants a…
Sponsor: Arvinas Inc.
NCT ID: NCT07023731
Sites in Texas: - Clinical Trial Site — Houston, Texas
- Clinical Trial Site — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Industry
This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participan…
Sponsor: Toray Industries, Inc
NCT ID: NCT06038578
Sites in Texas: - Texas Oncology Arlington North — Arlington, Texas
- Texas Oncology Bedford — Bedford, Texas
- Texas Oncology Dallas Methodist — Dallas, Texas
- Texas Oncology Dallas Medical City — Dallas, Texas
- Texas Oncology Dallas Presbyterian — Dallas, Texas
Phase 2 Recruiting Industry
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…
Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas